Navigation Links
Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline

Research by CMR Shows Revenue Derived from New Products Launched within the

Last Five Years has Dropped to Just 16% of Total Revenue in 2006

PHILADELPHIA, Aug. 15 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today issued its quarterly The Ones-to-Watch report, providing expert insight into the five most promising drugs to enter each new phase of clinical development between April and June 2007.

"This quarter's most promising drugs all have significant market potential and are associated with diseases and conditions that impact countless numbers of individuals," said Peter Robins, PhD, and editorial content manager, Thomson Scientific. "These important clinical developments are highly encouraging for innovation-based companies in a period when many pharmaceutical products are coming toward the end of their patent protection."

New research from CMR, a Thomson company, shows that revenue derived from new products (those launched within the last five years) dropped to just 16% of total revenue in 2006. And although the cost of research and development continues to rise, there is no sign of a sustained upturn in the number of new products reaching the market.

Which are the Ones-to-Watch this Quarter?

Topping this quarter's approval list is Novartis Vaccines & Diagnostics' Optaflu(R), a vaccine for influenza derived from a novel, proprietary cell line. Approved for use in the EU in June 2007, Novartis plans to file for US approval of Optaflu in 2008.

Second on our list is Wyeth, which is marketing Lybrel(TM) -- a combination of Levonorgestrel and ethinyl estradiol in a daily oral tablet which eliminates the menstrual cycle and is being trialed as a potential treatment for severe premenstrual syndromes.

Third is a drug launched in Japan in June 2007 for the treatment of incontinence and pollakiuria (frequent urination) under the name Staybla(R). Urinary incontinence is particularly prevalent in men and usually associated with aging. Where the problem is an overactive bladder, patients may benefit from the M1 and M3 muscarinic receptor imidafenacin, developed by Kyorin Pharmaceutical, Ono Pharmaceutical and LG Life Sciences.

Fourth is a drug for one of the most severe forms of epilepsy (Lennox- Gastaut Syndrome or LGS), affecting approximately 5% of the children who have the disease. Eisai's rufinamide, licensed from Novartis, is the first drug approved in the EU specifically for LGS. Eisai launched rufinamide in Germany, Australia and Scandinavia in June 2007 under the name Inovelon(TM). US filing is in process.

Finally for this section this quarter, Torisel(TM) is the brand name of temsirolimus, an analog of the mTOR inhibitor sirolimus (rapamycin) developed by Wyeth Research for the oral treatment of advanced renal cell carcinoma (RRC). Having received FDA approval in May 2007, the drug is now available to patients in the US, while approval is pending in the EU.

Following are the top five drugs in each category of phase changes:

The Five Most Promising Drugs Entering Phase III Trials

- trazodone, (Depression), Labopharm

- pimavanserin, (Schizophrenia), ACADIA Pharmaceuticals

- salmon calcitonin, (Osteoporosis/Paget's disease), Novartis/Nordic


- Generx(TM), (Coronary artery disease), Cardium Therapeutics

- fenofibrate and pravastatin, (Mixed dyslipidemia), Sciele

Pharma/Galephar PR

The Five Most Promising Drugs Entering Phase II Trials

- VSF-173, (Excessive sleepiness), Vanda Pharmaceuticals

- APD-125, (Insomnia), Arena

- Neugranin(TM), (Chemotherapy-induced neutropenia), CoGenesys

- Hepaconda(R) , (Hepatitis C), Giaconda

- GRC-6211, (Pain), Glenmark

The Five Most Promising Drugs Entering Phase I Trials

- Ad35 HIV-ENvA, (HIV infection), GenVec/NIAID Vaccine Research Center

- nestorone and estradiol (transdermal gel), (Female contraception),

Antares/Population Council

- Fluvacc, (Influenza), Avir Green Hills Biotechnology

- insulin oral gel capsule, (Diabetes), Oramed

- trodusquemine, (Obesity), Ganaera

About This Quarterly Report:

Data for this report was compiled and analyzed using Thomson Pharma(R), a comprehensive global pharmaceutical information solution that covers the entire drug discovery and development pipeline. Its competitive intelligence and strategic data can justify and speed decision-making, facilitate more focused collaboration, and encourage innovation.

For a copy of the full report with analysis, visit:

About The Thomson Corporation

The Thomson Corporation ( is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at

SOURCE Thomson Scientific

Copyright©2007 PR Newswire.

Related medicine technology :

1. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
2. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
6. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
7. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
8. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
9. Inspire Announces Presentations at Two European Scientific Conferences
10. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:11/30/2015)... RATON, Fla. , Nov. 30, 2015   ... (the Institute) announced today that it has finalized ... device start-up company with technology developed at Florida State ... publicly-funded research, and bridges early funding gaps for companies ... and research institutions. --> ...
(Date:11/30/2015)... Ended 30 September 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 ... 384,242 , 9.8 Hospital Management Service Income ... (18.3) Medical Insurance Administration Service Income , 2,780 ... Accessories Sales , 89,645 , 94,580 ... , 2,917 , (3.3) Gross Profit ...
(Date:11/30/2015)... -- PTS Diagnostics, the U.S.-based manufacturer of point-of-care biometric testing ... systems, and PTS Detect™ cotinine systems, has announced ... propel the company into the mHealth market. ... . The technology is a system that interfaces with ... tablets, and uses test strip technology already developed by ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Olympic Gold Medalists ... collaborating with brands across various categories through traditional and social media marketing campaigns ... elite group of Gold Medal Moms who can connect with today’s most important ...
(Date:11/30/2015)... ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. ... the nation’s leading networking organization exclusively for professional women, boasting 850,000 members and ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... programs of the19th Bi-National Convention of the Federation of Philippine American Chambers of ... in Las Vegas, Nevada. , 1Heart Caregiver Services, as an active delegate ...
(Date:11/30/2015)... ... 2015 , ... Until now, the St. Louis Fetal Care Institute ... Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. According ... 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is obese. ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase awareness of ... Your Mouth?” campaign to inform dentists that the technicians they trust could lack ...
Breaking Medicine News(10 mins):